Astion Pharma A S - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 25

Astion Pharma A S – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Astion Pharma A/S - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Astion Pharma A/S - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Astion Pharma A/S human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Astion Pharma A/S with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Astion Pharma A/S’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Astion Pharma A/S’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Astion Pharma A/S in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Astion Pharma A/S’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Astion Pharma A/S.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Astion Pharma A/S and identify potential opportunities in those areas.

List of Tables
List of Figures
Astion Pharma A/S Snapshot
Astion Pharma A/S Overview
Key Information
Key Facts
Astion Pharma A/S – Research and Development Overview
Key Therapeutic Areas
Astion Pharma A/S – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Astion Pharma A/S – Pipeline Products Glance
Astion Pharma A/S – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Astion Pharma A/S Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Astion Pharma A/S–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Astion Pharma A/S – Drug Profiles
ASF1057
Product Description
Mechanism of Action
R&D Progress
ASF-1096
Product Description
Mechanism of Action
R&D Progress
ASF-1097
Product Description
Mechanism of Action
R&D Progress
Astion Pharma A/S – Pipeline Analysis
Astion Pharma A/S – Pipeline Products by Therapeutic Class
Astion Pharma A/S Pipeline Products By Target
Astion Pharma A/S – Pipeline Products by Route of Administration
Astion Pharma A/S – Pipeline Products by Molecule Type
Astion Pharma A/S - Dormant Projects
Astion Pharma A/S – Locations And Subsidiaries
Head Office
Recent Developments
Aug 01, 2007: The European Medicines Evaluation Agency recommends Astion pharma's drug candidate ASF-1096 for orphan drug status
Financial Deals Landscape
Astion Pharma A/S, Deals Summary, 2004 to 2010
Astion Pharma A/S Detailed Deal Summary
Venture Financing
Astion Pharma Raises $6.5 Million In Venture Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Generic Defense Strategies: Lifecycle Management Strategies to Maximize Revenue in the Face of Growing Generic Competition
• Charter Schools - Global Outlook
• Sports and Fitness Nutrition - Global Strategic Business Report
• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Worldwide Industry & Market Opportunities and forecasts to 2014 for Microwaves Global Military & Space-Related Systems
• North America – Smart Weapons Markets and Technologies Outlook – 2013-2020
• Education Services - Global Strategic Business Report
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles